|1.||Wickline, Samuel A: 2 articles (04/2015 - 11/2013)|
|2.||Palekar, Rohun U: 2 articles (04/2015 - 11/2013)|
|3.||Gaut, Joseph P: 1 article (04/2015)|
|4.||Cui, Grace: 1 article (04/2015)|
|5.||Zhang, Huiying: 1 article (04/2015)|
|6.||Vemuri, Chandu: 1 article (04/2015)|
|7.||Chen, Junjie: 1 article (04/2015)|
|8.||Goette, Matthew: 1 article (04/2015)|
|9.||Hu, Lingzhi: 1 article (04/2015)|
|10.||Myerson, Jacob W: 1 article (11/2013)|
12/01/1999 - "In PPACK-treated blood, both NC (3.3-fold) and PC (2.7-fold) increased platelet attachment on elevation of the shear rate from 500 to 1640 s(-1), whereas in citrated blood, adhesion and thrombus growth on PC were negligible under the high shear rate, unlike on NC (1.9-fold increase). "
10/01/1994 - "In contrast to the systemic administration of PPACK, local delivery produced maximal inhibition of thrombosis without alterations in hemostasis."
10/01/1994 - "These results indicate that local delivery of the direct antithrombin PPACK, by either boundary layer infusion or static application techniques, effectively inhibits platelet-dependent thrombosis at doses that are several orders of magnitude less than the systemic dose required for an equivalent antithrombotic effect. "
10/01/1994 - "In addition, static exposure of a mural thrombus to solutions of PPACK at concentrations > or = 2.5 mg/mL for 15 minutes produced sustained inhibition of platelet-dependent thrombosis with no change in hemostatic measurements. "
06/01/1994 - "The inhibition of thrombosis associated with intravenous PPACK was dose related. "
04/21/2000 - "In addition, unlike the other three agents, which exhibited no significant changes in hematological parameters, PPACK demonstrated dose dependent thrombocytopenia. "
12/01/1984 - "Leukopenia and thrombocytopenia were observed in the Echis and Echis + PPACK groups.(ABSTRACT TRUNCATED AT 250 WORDS)"
06/01/1986 - "Hemolysis was observed only in the Echis group, whereas thrombocytopenia and leukopenia were noted in both the Echis and the Echis + PPACK groups. "
03/22/2013 - "D-Phe-Pro-Arg-chloromethyl ketone inhibition at the thrombin active site led to further local and long range consequences to thrombin-ABE I ligand complexes with the autolysis loop often most affected. "
12/15/1997 - "The protease active site was inhibited with D-Phe-Pro-Arg-chloromethylketone (PPACK) to reduce autolysis. "
09/20/1991 - "Although hirudin-thrombin and D-Phe-Pro-Arg-chloromethyl ketone-thrombin differ in conformation in the autolysis loop (Lys145 to Gly150), this is most likely due to different crystal packing interactions and changes in circular dichroism between the two are probably due to the inherent flexibility of the loop. "
04/01/2015 - "PPACK NP pretreatment prevented an increase in serum creatinine concentration within 24 h after ischemia-reperfusion, reflecting preserved renal function. "
07/01/1991 - "Infusion of the thrombin inhibitor, D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone (PPACK), during ischemia and reperfusion also preserved in part the relaxant response induced by thrombin (Emax of 30.0 +/- 5.1%; p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)"
|2.||arginine chloromethyl ketone
|5.||Citric Acid (Citrate)
|8.||Thromboplastin (Tissue Factor)
|9.||Protease Inhibitors (Protease Inhibitor)
|10.||Atrial Natriuretic Factor (ANF)